MedPath

Effect of selenium supplementation in the treatment of women with polycystic ovary syndrome candidate for IVF.

Phase 3
Conditions
Polycystic ovarian syndrome.
Polycystic ovarian syndrome
E28.2
Registration Number
IRCT20170513033941N23
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Patients with polycystic ovary syndrome.
Individuals aged 18 to 40 years.

Exclusion Criteria

Metabolic abnormalities such as diabetes, impaired glucose tolerance and thyroid dysfunction

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.
Secondary Outcome Measures
NameTimeMethod
Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-B. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.
© Copyright 2025. All Rights Reserved by MedPath